Alkermes ALKS
NASDAQ ALKS
$45.43 -0.06 (-0.13%)
As of: Sep 9, 2026 · 1:26 PM EDT

Alkermes (ALKS) Cash & Current Investments (2010 - 2026)

Alkermes' (ALKS) quarterly Cash & Current Investments came in at $656.6 million in Q2 2026, down 35.36% year-over-year from $1.0 billion in Q2 2025, and up 28.27% quarter-over-quarter from $511.9 million in Q1 2026.

Analysis

Alkermes (ALKS) Cash & Current Investments (2010 - 2026) Analysis & Trends

Alkermes (ALKS) has reported Cash & Current Investments for 17 consecutive years, with $656.6 million the latest figure, recorded in Q2 2026.

  • On a quarterly basis, Cash & Current Investments fell 35.36% year-over-year to $656.6 million in Q2 2026; TTM through Jun 2026 was $656.6 million, a 35.36% decrease from a year earlier, with the FY2025 full-year figure at $1.1 billion, up 48.97% from the prior year.
  • Cash & Current Investments was $656.6 million for Q2 2026 at Alkermes, up from $511.9 million in the prior quarter.
  • Over five years, Cash & Current Investments peaked at $1.1 billion in Q4 2025 and troughed at $511.9 million in Q1 2026.
  • A 5-year average of $776.2 million and a median of $762.6 million in 2023 frame the typical range for Cash & Current Investments.
  • Across the five-year window, Cash & Current Investments surged 53.25% in 2023 and plunged 42.1% in 2026, its largest moves.
  • Over 5 years, Cash & Current Investments stood at $608.5 million in 2022, then rose by 27.12% to $773.5 million in 2023, then retreated by 2.82% to $751.7 million in 2024, then soared by 48.97% to $1.1 billion in 2025, then sank by 41.37% to $656.6 million in 2026.
  • The last three Cash & Current Investments figures came in at $656.6 million (Q2 2026), $511.9 million (Q1 2026), and $1.1 billion (Q4 2025), per Business Quant data.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash & Current Investments (Qtr)
1 Johnson & Johnson 644.32 Bn 623.56 Bn 17.26 Bn 20.76 Bn
2 AbbVie 440.60 Bn 434.04 Bn 12.70 Bn 6.57 Bn
3 Merck 365.39 Bn 358.25 Bn 12.21 Bn 7.14 Bn
4 Novartis Ag 266.73 Bn 259.04 Bn 11.24 Bn 7.69 Bn
5 Pfizer 159.22 Bn 147.52 Bn 10.94 Bn 11.70 Bn
6 Sanofi 52.48 Bn 45.10 Bn 10.79 Bn 7.38 Bn
7 Revolution Medicines 44.21 Bn 44.21 Bn - -
8 Incyte 25.34 Bn 20.81 Bn 1.57 Bn 4.54 Bn
9 United Therapeutics 21.49 Bn 18.82 Bn 683.80 Mn 2.66 Bn
10 Alkermes 7.58 Bn 6.93 Bn 397.90 Mn 656.58 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 656.58 Mn
Mar 31, 2026 511.86 Mn
Dec 31, 2025 1.12 Bn
Sep 30, 2025 1.11 Bn
Jun 30, 2025 1.02 Bn
Mar 31, 2025 884.02 Mn
Dec 31, 2024 751.67 Mn
Sep 30, 2024 908.86 Mn
Jun 30, 2024 876.12 Mn
Mar 31, 2024 745.05 Mn
Dec 31, 2023 773.49 Mn
Sep 30, 2023 889.15 Mn
Jun 30, 2023 829.05 Mn
Mar 31, 2023 600.46 Mn
Dec 31, 2022 608.47 Mn
Sep 30, 2022 580.18 Mn
Jun 30, 2022 580.97 Mn
Mar 31, 2022 528.87 Mn
Dec 31, 2021 536.31 Mn
Sep 30, 2021 560.30 Mn